Actionable insights straight to your inbox

Equities logo

NY Times Writes Editorial Urging Trump to Widen Cannabis Research

The Old Gray Lady is urging Trump to warm to cannabis...
David N. Feldman is a partner at Duane Morris LLP, where he concentrates his practice on corporate and securities law and mergers and acquisitions, as well as general representation of public and private companies, entrepreneurs, investors, and private equity and venture capital firms. Mr. Feldman also advises small businesses with regard to alternatives to traditional financing through initial public offerings. His popular blog at www.DavidFeldmanBlog.com, focusing on entrepreneurship and the regulatory environment, has been recognized by LexisNexis as a Top 25 corporate law blog, and his videos appear on his YouTube channel, The Entrepreneur’s Advocate. Mr. Feldman is a 1985 graduate of the University of Pennsylvania Law School, where he was managing editor of the student newspaper, the Penn Law Forum, and a graduate of the Wharton School of the University of Pennsylvania. He has served as chair of the board of Wharton’s global alumni association.
David N. Feldman is a partner at Duane Morris LLP, where he concentrates his practice on corporate and securities law and mergers and acquisitions, as well as general representation of public and private companies, entrepreneurs, investors, and private equity and venture capital firms. Mr. Feldman also advises small businesses with regard to alternatives to traditional financing through initial public offerings. His popular blog at www.DavidFeldmanBlog.com, focusing on entrepreneurship and the regulatory environment, has been recognized by LexisNexis as a Top 25 corporate law blog, and his videos appear on his YouTube channel, The Entrepreneur’s Advocate. Mr. Feldman is a 1985 graduate of the University of Pennsylvania Law School, where he was managing editor of the student newspaper, the Penn Law Forum, and a graduate of the Wharton School of the University of Pennsylvania. He has served as chair of the board of Wharton’s global alumni association.

New York Times & Lode Van de Velde via Wikimedia Commons & PublicDomainPictures.net

The old gray lady, The New York Times, wrote an editorial last week encouraging the Trump Administration to significantly expand the opportunity for US researchers to grow and study cannabis. It reminded me a bit of the 2013 Sanjay Gupta MD special on cannabis on CNN. Gupta originally believed that pot is dangerous, a gateway drug, and its medical benefits are not proven. He then spent a year studying the drug and said, basically, not only do we need to do this, we need to do it right now.

The editorial cited a recent report from the National Academies of Sciences, Engineering and Medicine. The report says there is evidence to support that pot significantly helps chronic pain. They did say smoking pot makes driving more dangerous, but also said they found evidence that smoking pot does not increase the risk for cancers associated with tobacco use. But it also talks a lot about how there is not enough research on things like pot’s effect on the heart and the immune system.

The Times noted the NASEM’s statement that there are several “challenges and barriers” in conducting research on cannabis. The paper’s editors strongly urged Trump and the Congress, if they are not changing marijuana from a Schedule I drug, to at least “remove the regulatory barriers to research and let scientists get to work.” This humble blogger strongly agrees.

A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.